威斯康星州 的 非小细胞肺癌 临床试验
威斯康星州 有 45 项针对 非小细胞肺癌 的研究正在招募参与者。
威斯康星州 的城市
- Milwaukee22 项研究
- Madison16 项研究
- Green Bay14 项研究
- La Crosse10 项研究
- Wausau9 项研究
- Stevens Point8 项研究
- Sheboygan7 项研究
- Eau Claire7 项研究
- Manitowoc6 项研究
- Racine6 项研究
- Kenosha6 项研究
- Oshkosh6 项研究
- Watertown3 项研究
官方研究文本（英文）
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0129), Madison
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月5日 · NCT06345729Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Duluth Clinic Ashland, Ashland
- Bellin Memorial Hospital, Green Bay
- Froedtert Menomonee Falls Hospital, Menomonee Falls
- 以及另外 5 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月5日 · NCT07388524Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton, Appleton
- 以及另外 52 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月5日 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Duluth Clinic Ashland, Ashland
- Northwest Wisconsin Cancer Center, Ashland
- Essentia Health-Hayward Clinic, Hayward
- 以及另外 2 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Wisconsin Carbone Cancer Center, Madison
招募中1/2 期
12 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT04585750A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Local Institution - 0135, Madison
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT07680764Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #33, Milwaukee
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT05176483Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- Duluth Clinic Ashland, Ashland
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- 以及另外 18 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06498635Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Wisconsin Institute for Medical Research, Madison
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06625775A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- HSHS St. Vincent Hospital Regional Cancer Center, Green Bay
- Local Institution - 0421, Marshfield
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT07361510A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Milwaukee
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT05877599A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Mercyhealth, Janesville
招募中3 期
18 至 100 岁 · 所有性别 · 更新于 2026年9月25日 · NCT05920356A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Schofield
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06868277Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Minnesota Oncology Hematology, P.A., Hudson
- Froedtert Hospital/Medical College of Wisconsin, Milwaukee
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07222566Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Milwaukee
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06218914This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Aurora Cancer Care-Grafton, Grafton
- Aurora BayCare Medical Center, Green Bay
- Aurora St. Luke's Medical Center, Milwaukee
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06758401Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- Marshfield Clinic-Chippewa Center, Chippewa Falls
- Aurora Saint Luke's South Shore, Cudahy
- 以及另外 27 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT03191149Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- University Hospital and UW Health Clinics, Madison
- Medical College of Wisconsin, Milwaukee
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06890598Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Appleton
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT06357533Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Gundersen Lutheran Medical Center, La Crosse
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06712316A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- UW Health Carbone Cancer Center, Madison
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT07488676A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Medical College of Wisconsin, Milwaukee
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月18日 · NCT06855771HEARTS Trial for Thoracic Cancers
- University of Wisconsin - Madison, Madison
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT07132918ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- ThedaCare Regional Cancer Center, Appleton
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT05059444A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Froedtert Hospital - Clinical Cancer Center, Milwaukee
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月10日 · NCT06914128A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Medical College of Wisconsin, Milwaukee
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月8日 · NCT06561685A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical, Madison
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月8日 · NCT06119581A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Ascension Network - St Elizabeth's Hospital, Appleton
- Ascension Columbia St. Mary's, Milwaukee
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月8日 · NCT06793215Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Eau Claire
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月4日 · NCT07291037A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- The Board of Regents of the University of Wisconsin, Madison
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月2日 · NCT07070232Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Research Site, Milwaukee
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月26日 · NCT06350097MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- University of Wisconsin - Carbone Cancer Center, Madison
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月24日 · NCT06586515A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- University of Wisconsin- Madison, Madison
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年8月11日 · NCT05592626Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
- Northwest Wisconsin Cancer Center, Ashland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年7月14日 · NCT06686771KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- University of Wisconsin (Carbone Cancer Center), Madison
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年6月8日 · NCT06026410Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Langlade Hospital and Cancer Center, Antigo
- Duluth Clinic Ashland, Ashland
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- 以及另外 27 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年6月3日 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Duluth Clinic Ashland, Ashland
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- Aurora Saint Luke's South Shore, Cudahy
- 以及另外 18 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年5月6日 · NCT06116682Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Duluth Clinic Ashland, Ashland
- Aurora Cancer Care-Southern Lakes VLCC, Burlington
- Aurora Saint Luke's South Shore, Cudahy
- 以及另外 26 项
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年5月5日 · NCT06616584Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- Univeristy of Wisconsin, Madison
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年5月5日 · NCT04317534Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Duluth Clinic Ashland, Ashland
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- Gundersen Lutheran Medical Center, La Crosse
- 以及另外 5 项
招募中2 期
18 Minutes · 所有性别 · 更新于 2026年5月5日 · NCT06031688数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。